- Home
- NVNI vs MDCX Comparison
NVNI vs MDCX Comparison
Compare NVNI & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NVNI | MDCX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | Brazil | United States |
| Employees | 618 | 16 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVNI | MDCX |
|---|---|---|
| Price | $1.12 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 70.4K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.25 |
| 52 Week High | $4.94 | $8.72 |
Technical Indicators
Market Signals| Indicator | NVNI | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 36.87 |
| Support Level | $1.10 | $0.25 |
| Resistance Level | $1.37 | $0.36 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 32.61 | 24.59 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.